Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions

Alessia Savoldi, Elena Carrara, David Y Graham, Michela Conti, Evelina Tacconelli, Alessia Savoldi, Elena Carrara, David Y Graham, Michela Conti, Evelina Tacconelli

Abstract

Background & aims: In 2017, the World Health Organization (WHO) designated clarithromycin-resistant Helicobacter pylori a high priority for antibiotic research and development. However, there are no clear data on the global distribution of resistance or its clinical effects. We performed a systematic review and meta-analysis to assess the distribution of H pylori resistance to commonly used antibiotics and to measure the association between antibiotic resistance and treatment failure.

Methods: We searched publication databases for studies that assessed rates of H pylori resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, or tetracycline. Pooled estimates of primary and secondary resistance and 95% confidence intervals (CIs) were grouped by WHO region. The association between antibiotic resistance and treatment failure was measured by extracting data on treatment efficacy in patients with resistant and susceptible isolates and pooling odds ratios with 95% CIs.

Results: We identified 178 studies, comprising 66,142 isolates from 65 countries. Primary and secondary resistance rates to clarithromycin, metronidazole, and levofloxacin were ≥15% in all WHO regions, except primary clarithromycin resistance in the Americas (10%; 95% CI, 4%-16%) and South-East Asia region (10%; 95% CI, 5%-16%) and primary levofloxacin resistance in the European region (11%; 95% CI, 9%-13%). There was considerable heterogeneity (I2 > 75%) among all analyses-this might have resulted from the grouping of resistance rates by country. Increasing antibiotic resistance was observed in most WHO regions. Resistance to clarithromycin was significantly associated with failure of clarithromycin-containing regimens (odds ratio, 6.97; 95% CI, 5.23-9.28; P < .001).

Conclusions: Resistance of H pylori to antibiotics has reached alarming levels worldwide, which has a great effect on efficacy of treatment. Local surveillance networks are required to select appropriate eradication regimens for each region.

Keywords: Bacterial Infection; Drug; Epidemiology; Prevalence.

Conflict of interest statement

Conflicts of interest

The remaining author discloses no conflicts.

Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1.
Figure 1.
Flow chart of study selection.
Figure 2.
Figure 2.
Pooled prevalence (2006–2016) of resistance to clarithromycin (A), metronidazole (B), and levofloxacin (C) by country.

References

    1. Hooi JKY, Lai WJ, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420–429.
    1. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995;9(Suppl 2):33–39.
    1. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6–30.
    1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum; 2012;100(Pt B):1–441.
    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:359–386.
    1. Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016;150:1113–1124.
    1. Rokkas T, Rokka A, Portincasa P, et al. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol 2017;30:414–423.
    1. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: is the end coming? World J Gastrointest Pharmacol Ther 2015;6:183–198.
    1. Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014;20:5252–5262.
    1. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12: 275–278.
    1. Arslan N, Yilmaz N, Demiray-Gurbuz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017;23:2854–2869.
    1. Kuo YT, Liou MJ, El Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017;2:707–715.
    1. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016;43:514–533.
    1. Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016; 6:CD009034.
    1. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori infection in adults. Gastroenterology 2016;151:51–69.
    1. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18:318–327.
    1. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Br Med J 2015;354:i4086.
    1. Munn Z, Moola S, Riitano D, et al. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 2014;3:123–128.
    1. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews. Version 5.1.0 [updated March 2011]. Available at: . Accessed December 14, 2017.
    1. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409–414.
    1. Camargo MC, García A, Riquelme A, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014;109:485–495.
    1. Yousefi-Avarvand A, Vaez H, Tafaghodi M, et al. Antibiotic resistance of Helicobacter pylori in Iranian children: a systematic review and meta-analysis. Microb Drug Resist 2018;24:980–986.
    1. Lopes AI, Oleastro M, Palha A, et al. Antibiotic-resistant Helicobacter pylori strains in Portuguese children. Pediatr Infect Dis J 2005;24:404–409.
    1. Liu G, Xu X, He L, et al. Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children. Helicobacter 2011;16:356–362.
    1. Pereira FS, Bucaretchi F, Stephan C, et al. Self-medication in children and adolescents. J Pediatr (Rio J) 2007; 83:453–458.
    1. Megraud FH pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53: 1374–1384.
    1. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14:742–750.
    1. Lim SG, Park RW, Shin SJ, et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis 2016;48:385–390.
    1. Shin WG, Lee SW, Baik GH, et al. Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use: nationwide survey. Helicobacter 2016;21:266–278.
    1. Marin AC, Nyssen OP, McNicholl AG, et al. Efficacy and safety of quinolone-containing rescue therapies after the failure of non-bismuth quadruple treatments for Helicobacter pylori eradication: systematic review and meta-analysis. Drugs 2017;77:765–776.
    1. Chen PY, Wu MS, Chen CY, et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 2016;44:427–437.
    1. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan, 2009 revised edition. Helicobacter 2010;15:1–20.
    1. Bardhan K, Bayerdörffer E, Veldhuyzen Van Zanten SJ, et al. The HOMER study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000;5:196–201.
    1. McNicholl AG, Gasbarrini A, Tepes B, et al. Pan-European registry on H. pylori management (HP-EuReg): bacterial resistance. Gastroenterology 2015;148(Suppl 1):S417.
    1. Shiotani A, Lu H, Dore MP, et al. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med 2017;84:310–318.
    1. Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol 2017;14:383–384.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する